Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) [Phase 1, Phase 2]

View source ↗

Summary

The MATINS Phase 1/2 trial evaluating FP-1305 in cancer patients has completed and posted results, reporting safety, tolerability, and preliminary efficacy data…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• FP-1305

Snippet

Sponsor: Faron Pharmaceuticals Ltd | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-04-02